Literature DB >> 14634010

Modulation of prion protein oligomerization, aggregation, and beta-sheet conversion by 4,4'-dianilino-1,1'-binaphthyl-5,5'-sulfonate (bis-ANS).

Yraima Cordeiro1, Luís Maurício T R Lima, Mariana P B Gomes, Débora Foguel, Jerson L Silva.   

Abstract

The prion protein (PrP) is the major agent implicated in the diseases known as transmissible spongiform encephalopathies. The onset of transmissible spongiform encephalopathy is related to a change in conformation of the PrP(C), which loses most of its alpha-helical content, becoming a beta-sheet-rich protein, known as PrP(Sc). Here we have used two Syrian hamster prion domains (PrP 109-141 and PrP 109-149) and the murine recombinant PrP (rPrP 23-231) to investigate the effects of anilino-naphtalene compounds on prion oligomerization and aggregation. Aggregation in the presence of bis-ANS (4,4'-dianilino-1,1'-binaphthyl-5,5'-sulfonate), ANS (1-anilinonaphthalene-8-sulfonate), and AmNS (1-amino-5-naphtalenesulfonate) was monitored. Bis-ANS was the most effective inhibitor of prion peptide aggregation. Bis-ANS binds strongly to rPrP 23-231 leading to a substantial increase in beta-sheet content and to limited oligomerization. More strikingly, the binding of bis-ANS to full-length rPrP is diminished by the addition of nanomolar concentrations of oligonucleotides, demonstrating that they compete for the same binding site. Thus, bis-ANS displays properties similar to those of nucleic acids, causing oligomerization and conversion to beta-sheet (Cordeiro, Y., Machado, F., Juliano, L., Juliano, M. A., Brentani, R. R., Foguel, D., and Silva, J. L. (2001) J. Biol. Chem. 276, 49400-49409). This dual effect of bis-ANS on prion protein makes this compound highly important to sequester crucial conformations of the protein, which may be useful to the understanding of the disease and to serve as a lead for the development of new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634010     DOI: 10.1074/jbc.M312262200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Fluorescent N-arylaminonaphthalene sulfonate probes for amyloid aggregation of alpha-synuclein.

Authors:  M Soledad Celej; Elizabeth A Jares-Erijman; Thomas M Jovin
Journal:  Biophys J       Date:  2008-03-13       Impact factor: 4.033

2.  Biophysical and morphological studies on the dual interaction of non-octarepeat prion protein peptides with copper and nucleic acids.

Authors:  Juliana A P Chaves; Carolina Sanchez-López; Mariana P B Gomes; Tháyna Sisnande; Bruno Macedo; Vanessa End de Oliveira; Carolina A C Braga; Luciana P Rangel; Jerson L Silva; Liliana Quintanar; Yraima Cordeiro
Journal:  J Biol Inorg Chem       Date:  2014-02-21       Impact factor: 3.358

Review 3.  Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases.

Authors:  Anna Villar-Piqué; Matthias Schmitz; Niccolò Candelise; Salvador Ventura; Franc Llorens; Inga Zerr
Journal:  Mol Neurobiol       Date:  2018-02-10       Impact factor: 5.590

4.  The amino-terminal PrP domain is crucial to modulate prion misfolding and aggregation.

Authors:  Yraima Cordeiro; Julia Kraineva; Mariana P B Gomes; Marilene H Lopes; Vilma R Martins; Luís M T R Lima; Débora Foguel; Roland Winter; Jerson L Silva
Journal:  Biophys J       Date:  2005-07-22       Impact factor: 4.033

Review 5.  Chaperones and proteases: cellular fold-controlling factors of proteins in neurodegenerative diseases and aging.

Authors:  Marie-Pierre Hinault; Anat Ben-Zvi; Pierre Goloubinoff
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

6.  Specific soluble oligomers of amyloid-β peptide undergo replication and form non-fibrillar aggregates in interfacial environments.

Authors:  Amit Kumar; Lea C Paslay; Daniel Lyons; Sarah E Morgan; John J Correia; Vijayaraghavan Rangachari
Journal:  J Biol Chem       Date:  2012-04-27       Impact factor: 5.157

7.  Self-aggregation of a recombinant form of the propeptide NH2-terminal of the precursor of pulmonary surfactant protein SP-B: a conformational study.

Authors:  A Bañares-Hidalgo; A Bolaños-Gutiérrez; F Gil; E J Cabré; J Pérez-Gil; P Estrada
Journal:  J Ind Microbiol Biotechnol       Date:  2008-09-17       Impact factor: 3.346

8.  Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches.

Authors:  Natalia C Ferreira; Icaro A Marques; Wesley A Conceição; Bruno Macedo; Clarice S Machado; Alessandra Mascarello; Louise Domeneghini Chiaradia-Delatorre; Rosendo Augusto Yunes; Ricardo José Nunes; Andrew G Hughson; Lynne D Raymond; Pedro G Pascutti; Byron Caughey; Yraima Cordeiro
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

9.  Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions.

Authors:  Déborah Tribouillard-Tanvier; Vincent Béringue; Nathalie Desban; Fabienne Gug; Stéphane Bach; Cécile Voisset; Hervé Galons; Hubert Laude; Didier Vilette; Marc Blondel
Journal:  PLoS One       Date:  2008-04-23       Impact factor: 3.240

10.  Prion protein complexed to N2a cellular RNAs through its N-terminal domain forms aggregates and is toxic to murine neuroblastoma cells.

Authors:  Mariana P B Gomes; Thiago A Millen; Priscila S Ferreira; Narcisa L Cunha e Silva; Tuane C R G Vieira; Marcius S Almeida; Jerson L Silva; Yraima Cordeiro
Journal:  J Biol Chem       Date:  2008-05-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.